Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma

Benjamin T. Ristau, Daniel M. Geynisman

Research output: Contribution to journalEditorial

1 Scopus citations
Original languageEnglish
Pages (from-to)210-212
Number of pages3
JournalEuropean Urology
Volume71
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • Carcinoma, Renal Cell
  • Cost-Benefit Analysis
  • Humans
  • Kidney Neoplasms
  • Neoplasms, Second Primary
  • Quality-Adjusted Life Years

Fingerprint

Dive into the research topics of 'Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this